 |
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
 |
|
|
 |
 |
 |
 |
Enzyme class:
|
 |
E.C.3.2.1.52
- Beta-N-acetylhexosaminidase.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Hydrolysis of terminal non-reducing N-acetyl-D-hexosamine residues in N-acetyl-beta-D-hexosaminides.
|
 |
 |
 |
 |
 |
 |
 |
|
 |
|
 |
|
|
Gene Ontology (GO) functional annotation
|
|
|
|
 |
 |
 |
|
 |
 |
 |
 |
|
 |
|
Cellular component
|
membrane
|
4 terms
|
 |
|
Biological process
|
metabolic process
|
25 terms
|
 |
|
Biochemical function
|
catalytic activity
|
11 terms
|
 |
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
DOI no:
|
J Mol Biol
327:1093-1109
(2003)
|
|
PubMed id:
|
|
|
|
|
| |
|
Crystal structure of human beta-hexosaminidase B: understanding the molecular basis of Sandhoff and Tay-Sachs disease.
|
|
B.L.Mark,
D.J.Mahuran,
M.M.Cherney,
D.Zhao,
S.Knapp,
M.N.James.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
In humans, two major beta-hexosaminidase isoenzymes exist: Hex A and Hex B. Hex
A is a heterodimer of subunits alpha and beta (60% identity), whereas Hex B is a
homodimer of beta-subunits. Interest in human beta-hexosaminidase stems from its
association with Tay-Sachs and Sandhoff disease; these are prototypical
lysosomal storage disorders resulting from the abnormal accumulation of
G(M2)-ganglioside (G(M2)). Hex A degrades G(M2) by removing a terminal
N-acetyl-D-galactosamine (beta-GalNAc) residue, and this activity requires the
G(M2)-activator, a protein which solubilizes the ganglioside for presentation to
Hex A. We present here the crystal structure of human Hex B, alone (2.4A) and in
complex with the mechanistic inhibitors GalNAc-isofagomine (2.2A) or
NAG-thiazoline (2.5A). From these, and the known X-ray structure of the
G(M2)-activator, we have modeled Hex A in complex with the activator and
ganglioside. Together, our crystallographic and modeling data demonstrate how
alpha and beta-subunits dimerize to form either Hex A or Hex B, how these
isoenzymes hydrolyze diverse substrates, and how many documented point mutations
cause Sandhoff disease (beta-subunit mutations) and Tay-Sachs disease
(alpha-subunit mutations).
|
|
|
|
|
| |
Selected figure(s)
|
|
|
| |
 |
 |
|
 |
|
 |
Figure 2.
Figure 2. Ribbon diagram of human b-hexosaminidase B. The
b-subunits of the Hex B homodimer are colored with domain I in
green and domain II in blue (the eight parallel strands of the
b-barrel of domain II is colored sky blue). What appear to be
common structural features of family 20 glycosidases is the
absence of regular a-helices at positions a5 and a7 of the
(b/a)[8]-barrel structure of domain II and an additional
C-terminal helix following helix a8. This additional helix packs
between domains I and II, spatially orienting the two domains
relative to each other. Helix a7 consists of only two turns and
is part of an extended loop that forms a major portion of the
dimer interface. The subunits are related at the dimer interface
by a crystallographic 2-fold symmetry axis running perpendicular
to the page. The N and C termini created as a result of
post-translational processing are numbered by residue. The
labels N and C denote the extreme N (residue 55) and C (residue
552) termini visible within the electron density. The disulfide
bonds Cys91-Cys137, Cys309-Cys360 and Cys534-Cys551 are drawn in
brown, magenta and yellow, respectively. The analogue of the
reaction intermediate NAG-thiazoline, bound in the active site
of each subunit is drawn as a space-filling model with carbon
atoms in gray, oxygen in red, nitrogen in blue and sulfur in
yellow. The active sites of each subunit are located 37 Å
apart. All ribbon diagrams were drawn with Molscript[82.] and
rendered with Raster3D [83.] unless otherwise indicated.
|
 |
Figure 6.
Figure 6. Predicted model of human Hex A-G[M2]-activator
quaternary complex. (a and b) Two views of the predicted
quaternary complex. Residues of the a-subunit identical to those
of the b-subunit are colored blue, non-identical residues are
colored light brown. Most of the conserved amino acids in the a
and b-subunits are located in (b/a)[8]-barrel of domain II. The
b-subunit is colored gray, with residues of the active site
distinguished in orange. The G[M2]-activator protein complex
(G[M2]-AP) docks into a large groove between the two subunits so
that the terminal non-reducing GalNAc sugar on G[M2] can be
presented to the a-subunit active site and removed. Two surface
loops (magenta and green), present only on the a-subunit,
interact with the docked activator protein and appear to be
involved in creating a docking site unique to the a-subunit. The
magenta colored loop is proteolytically removed from the
b-subunit during post-translational processing and may represent
a modification that regulates the metabolic function of this
subunit. (c) Model of the GM2 oligosaccharide (yellow) bound to
the a-subunit active site (gray). The distorted boat
conformation of the terminal GalNAc to be removed (Gal, labeled
in blue) and the pseudo-axial orientation of the scissile bond
and leaving group are based on crystallographic observations of
the Michaelis complex of chitobiose bound to SmCHB.[20.] By
incorporating these conformational restraints into the model,
only one reasonable position could be found for the sialic acid
residue (labeled SIA) within the active site pocket. Once
positioned, the negatively charged carboxylate of the sialic
acid, which can only be accommodated by the a-subunit, was found
to come within hydrogen bonding distance of Arg424, a positively
charged residue that is unique to the a-subunit (the b-subunit
contains a Leu at this position). aGlu394 and aAsn423 (which are
both Asp residues in the b-subunit) are believed to help hold
Arg424 into position. Arg424, in turn, stabilizes the negatively
charged caboxylate of the sialic acid of the substrate via
electrostatic and hydrogen-bonding interactions. The general
acid-base residue, Glu323 (Glu355 in the b-subunit), can be seen
interacting with the glycosidic oxygen atom of the scissile bond.
|
 |
|
|
|
| |
The above figures are
reprinted
by permission from Elsevier:
J Mol Biol
(2003,
327,
1093-1109)
copyright 2003.
|
|
| |
Figures were
selected
by the author.
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
 |
| |
PubMed id
|
 |
Reference
|
 |
|
|
|
 |
H.Usuki,
Y.Yamamoto,
Y.Kumagai,
T.Nitoda,
H.Kanzaki,
and
T.Hatanaka
(2011).
MS/MS fragmentation-guided search of TMG-chitooligomycins and their structure-activity relationship in specific β-N-acetylglucosaminidase inhibition.
|
| |
Org Biomol Chem, 9,
2943-2951.
|
 |
|
|
|
|
 |
J.T.Clarke,
D.J.Mahuran,
S.Sathe,
E.H.Kolodny,
B.A.Rigat,
J.A.Raiman,
and
M.B.Tropak
(2011).
An open-label Phase I/II clinical trial of pyrimethamine for the treatment of patients affected with chronic GM2 gangliosidosis (Tay-Sachs or Sandhoff variants).
|
| |
Mol Genet Metab, 102,
6.
|
 |
|
|
|
|
 |
Y.Yang,
T.Liu,
Y.Yang,
Q.Wu,
Q.Yang,
and
B.Yu
(2011).
Synthesis, Evaluation, and Mechanism of N,N,N-Trimethyl-D-glucosamine-(1→4)-chitooligosaccharides as Selective Inhibitors of Glycosyl Hydrolase Family 20 β-N-Acetyl-D-hexosaminidases.
|
| |
Chembiochem, 12,
457-467.
|
 |
|
|
|
|
 |
H.C.Dorfmueller,
V.S.Borodkin,
M.Schimpl,
X.Zheng,
R.Kime,
K.D.Read,
and
D.M.van Aalten
(2010).
Cell-penetrant, nanomolar O-GlcNAcase inhibitors selective against lysosomal hexosaminidases.
|
| |
Chem Biol, 17,
1250-1255.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
K.Slámová,
R.Gazák,
P.Bojarová,
N.Kulik,
R.Ettrich,
H.Pelantová,
P.Sedmera,
and
V.Kren
(2010).
4-Deoxy-substrates for beta-N-acetylhexosaminidases: how to make use of their loose specificity.
|
| |
Glycobiology, 20,
1002-1009.
|
 |
|
|
|
|
 |
M.B.Tropak,
S.W.Bukovac,
B.A.Rigat,
S.Yonekawa,
W.Wakarchuk,
and
D.J.Mahuran
(2010).
A sensitive fluorescence-based assay for monitoring GM2 ganglioside hydrolysis in live patient cells and their lysates.
|
| |
Glycobiology, 20,
356-365.
|
 |
|
|
|
|
 |
T.M.Gloster,
and
D.J.Vocadlo
(2010).
Mechanism, Structure, and Inhibition of O-GlcNAc Processing Enzymes.
|
| |
Curr Signal Transduct Ther, 5,
74-91.
|
 |
|
|
|
|
 |
Z.S.Derewenda
(2010).
Application of protein engineering to enhance crystallizability and improve crystal properties.
|
| |
Acta Crystallogr D Biol Crystallogr, 66,
604-615.
|
 |
|
|
|
|
 |
H.C.Dorfmueller,
V.S.Borodkin,
M.Schimpl,
and
D.M.van Aalten
(2009).
GlcNAcstatins are nanomolar inhibitors of human O-GlcNAcase inducing cellular hyper-O-GlcNAcylation.
|
| |
Biochem J, 420,
221-227.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
J.Intra,
F.Cenni,
G.Pavesi,
M.Pasini,
and
M.E.Perotti
(2009).
Interspecific analysis of the glycosidases of the sperm plasma membrane in Drosophila.
|
| |
Mol Reprod Dev, 76,
85.
|
 |
|
|
|
|
 |
M.D.Balcewich,
K.A.Stubbs,
Y.He,
T.W.James,
G.J.Davies,
D.J.Vocadlo,
and
B.L.Mark
(2009).
Insight into a strategy for attenuating AmpC-mediated beta-lactam resistance: structural basis for selective inhibition of the glycoside hydrolase NagZ.
|
| |
Protein Sci, 18,
1541-1551.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
M.Pasztoi,
G.Nagy,
P.Geher,
T.Lakatos,
K.Toth,
K.Wellinger,
P.Pocza,
B.Gyorgy,
M.C.Holub,
A.Kittel,
K.Paloczy,
M.Mazan,
P.Nyirkos,
A.Falus,
and
E.I.Buzas
(2009).
Gene expression and activity of cartilage-degrading glycosidases in human rheumatoid arthritis and osteoarthritis synovial fibroblasts.
|
| |
Arthritis Res Ther, 11,
R68.
|
 |
|
|
|
|
 |
M.Wendeler,
and
K.Sandhoff
(2009).
Hexosaminidase assays.
|
| |
Glycoconj J, 26,
945-952.
|
 |
|
|
|
|
 |
S.Zampieri,
M.Filocamo,
E.Buratti,
M.Stroppiano,
K.Vlahovicek,
N.Rosso,
E.Bignulin,
S.Regis,
F.Carnevale,
B.Bembi,
and
A.Dardis
(2009).
Molecular and functional analysis of the HEXB gene in Italian patients affected with Sandhoff disease: identification of six novel alleles.
|
| |
Neurogenetics, 10,
49-58.
|
 |
|
|
|
|
 |
D.G.Hogenkamp,
Y.Arakane,
K.J.Kramer,
S.Muthukrishnan,
and
R.W.Beeman
(2008).
Characterization and expression of the beta-N-acetylhexosaminidase gene family of Tribolium castaneum.
|
| |
Insect Biochem Mol Biol, 38,
478-489.
|
 |
|
|
|
|
 |
J.Intra,
G.Pavesi,
and
D.S.Horner
(2008).
Phylogenetic analyses suggest multiple changes of substrate specificity within the glycosyl hydrolase 20 family.
|
| |
BMC Evol Biol, 8,
214.
|
 |
|
|
|
|
 |
J.Wada,
T.Ando,
M.Kiyohara,
H.Ashida,
M.Kitaoka,
M.Yamaguchi,
H.Kumagai,
T.Katayama,
and
K.Yamamoto
(2008).
Bifidobacterium bifidum lacto-N-biosidase, a critical enzyme for the degradation of human milk oligosaccharides with a type 1 structure.
|
| |
Appl Environ Microbiol, 74,
3996-4004.
|
 |
|
|
|
|
 |
P.M.Fischer
(2008).
Turning down tau phosphorylation.
|
| |
Nat Chem Biol, 4,
448-449.
|
 |
|
|
|
|
 |
G.H.Maegawa,
M.Tropak,
J.Buttner,
T.Stockley,
F.Kok,
J.T.Clarke,
and
D.J.Mahuran
(2007).
Pyrimethamine as a potential pharmacological chaperone for late-onset forms of GM2 gangliosidosis.
|
| |
J Biol Chem, 282,
9150-9161.
|
 |
|
|
|
|
 |
H.Akeboshi,
Y.Chiba,
Y.Kasahara,
M.Takashiba,
Y.Takaoka,
M.Ohsawa,
Y.Tajima,
I.Kawashima,
D.Tsuji,
K.Itoh,
H.Sakuraba,
and
Y.Jigami
(2007).
Production of recombinant beta-hexosaminidase A, a potential enzyme for replacement therapy for Tay-Sachs and Sandhoff diseases, in the methylotrophic yeast Ogataea minuta.
|
| |
Appl Environ Microbiol, 73,
4805-4812.
|
 |
|
|
|
|
 |
K.A.Stubbs,
M.Balcewich,
B.L.Mark,
and
D.J.Vocadlo
(2007).
Small molecule inhibitors of a glycoside hydrolase attenuate inducible AmpC-mediated beta-lactam resistance.
|
| |
J Biol Chem, 282,
21382-21391.
|
 |
|
PDB code:
|
 |
|
|
|
|
|
 |
M.B.Tropak,
and
D.Mahuran
(2007).
Lending a helping hand, screening chemical libraries for compounds that enhance beta-hexosaminidase A activity in GM2 gangliosidosis cells.
|
| |
FEBS J, 274,
4951-4961.
|
 |
|
|
|
|
 |
M.B.Tropak,
J.E.Blanchard,
S.G.Withers,
E.D.Brown,
and
D.Mahuran
(2007).
High-throughput screening for human lysosomal beta-N-Acetyl hexosaminidase inhibitors acting as pharmacological chaperones.
|
| |
Chem Biol, 14,
153-164.
|
 |
|
|
|
|
 |
R.Ettrich,
V.Kopecký,
K.Hofbauerová,
V.Baumruk,
P.Novák,
P.Pompach,
P.Man,
O.Plíhal,
M.Kutý,
N.Kulik,
J.Sklenár,
H.Ryslavá,
V.Kren,
and
K.Bezouska
(2007).
Structure of the dimeric N-glycosylated form of fungal beta-N-acetylhexosaminidase revealed by computer modeling, vibrational spectroscopy, and biochemical studies.
|
| |
BMC Struct Biol, 7,
32.
|
 |
|
|
|
|
 |
S.G.Manuel,
C.Ragunath,
H.B.Sait,
E.A.Izano,
J.B.Kaplan,
and
N.Ramasubbu
(2007).
Role of active-site residues of dispersin B, a biofilm-releasing beta-hexosaminidase from a periodontal pathogen, in substrate hydrolysis.
|
| |
FEBS J, 274,
5987-5999.
|
 |
|
|
|
|
 |
T.Okada,
S.Ishiyama,
H.Sezutsu,
A.Usami,
T.Tamura,
K.Mita,
K.Fujiyama,
and
T.Seki
(2007).
Molecular cloning and expression of two novel beta-N-acetylglucosaminidases from silkworm Bombyx mori.
|
| |
Biosci Biotechnol Biochem, 71,
1626-1635.
|
 |
|
|
|
|
 |
G.H.Maegawa,
T.Stockley,
M.Tropak,
B.Banwell,
S.Blaser,
F.Kok,
R.Giugliani,
D.Mahuran,
and
J.T.Clarke
(2006).
The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported.
|
| |
Pediatrics, 118,
e1550-e1562.
|
 |
|
|
|
|
 |
M.J.Lemieux,
B.L.Mark,
M.M.Cherney,
S.G.Withers,
D.J.Mahuran,
and
M.N.James
(2006).
Crystallographic structure of human beta-hexosaminidase A: interpretation of Tay-Sachs mutations and loss of GM2 ganglioside hydrolysis.
|
| |
J Mol Biol, 359,
913-929.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
M.Wendeler,
N.Werth,
T.Maier,
G.Schwarzmann,
T.Kolter,
M.Schoeniger,
D.Hoffmann,
T.Lemm,
W.Saenger,
and
K.Sandhoff
(2006).
The enzyme-binding region of human GM2-activator protein.
|
| |
FEBS J, 273,
982-991.
|
 |
|
|
|
|
 |
N.Tomiya,
S.Narang,
J.Park,
B.Abdul-Rahman,
O.Choi,
S.Singh,
J.Hiratake,
K.Sakata,
M.J.Betenbaugh,
K.B.Palter,
and
Y.C.Lee
(2006).
Purification, characterization, and cloning of a Spodoptera frugiperda Sf9 beta-N-acetylhexosaminidase that hydrolyzes terminal N-acetylglucosamine on the N-glycan core.
|
| |
J Biol Chem, 281,
19545-19560.
|
 |
|
|
|
|
 |
R.J.Dennis,
E.J.Taylor,
M.S.Macauley,
K.A.Stubbs,
J.P.Turkenburg,
S.J.Hart,
G.N.Black,
D.J.Vocadlo,
and
G.J.Davies
(2006).
Structure and mechanism of a bacterial beta-glucosaminidase having O-GlcNAcase activity.
|
| |
Nat Struct Mol Biol, 13,
365-371.
|
 |
|
PDB codes:
|
 |
|
|
|
|
|
 |
T.Itakura,
A.Kuroki,
Y.Ishibashi,
D.Tsuji,
E.Kawashita,
Y.Higashine,
H.Sakuraba,
S.Yamanaka,
and
K.Itoh
(2006).
Inefficiency in GM2 ganglioside elimination by human lysosomal beta-hexosaminidase beta-subunit gene transfer to fibroblastic cell line derived from Sandhoff disease model mice.
|
| |
Biol Pharm Bull, 29,
1564-1569.
|
 |
|
|
|
|
 |
M.S.Macauley,
G.E.Whitworth,
A.W.Debowski,
D.Chin,
and
D.J.Vocadlo
(2005).
O-GlcNAcase uses substrate-assisted catalysis: kinetic analysis and development of highly selective mechanism-inspired inhibitors.
|
| |
J Biol Chem, 280,
25313-25322.
|
 |
|
|
|
|
 |
T.Kolter,
F.Winau,
U.E.Schaible,
M.Leippe,
and
K.Sandhoff
(2005).
Lipid-binding proteins in membrane digestion, antigen presentation, and antimicrobial defense.
|
| |
J Biol Chem, 280,
41125-41128.
|
 |
|
|
|
|
 |
T.Kolter,
and
K.Sandhoff
(2005).
Principles of lysosomal membrane digestion: stimulation of sphingolipid degradation by sphingolipid activator proteins and anionic lysosomal lipids.
|
| |
Annu Rev Cell Dev Biol, 21,
81.
|
 |
|
|
|
|
 |
A.H.Futerman,
and
G.van Meer
(2004).
The cell biology of lysosomal storage disorders.
|
| |
Nat Rev Mol Cell Biol, 5,
554-565.
|
 |
|
|
|
|
 |
I.Sinici,
M.B.Tropak,
D.J.Mahuran,
and
H.A.Ozkara
(2004).
Assessing the severity of the small inframe deletion mutation in the alpha-subunit of beta-hexosaminidase A found in the Turkish population by reproducing it in the more stable beta-subunit.
|
| |
J Inherit Metab Dis, 27,
747-756.
|
 |
|
|
|
|
 |
M.B.Tropak,
S.P.Reid,
M.Guiral,
S.G.Withers,
and
D.Mahuran
(2004).
Pharmacological enhancement of beta-hexosaminidase activity in fibroblasts from adult Tay-Sachs and Sandhoff Patients.
|
| |
J Biol Chem, 279,
13478-13487.
|
 |
|
|
|
|
 |
M.Wendeler,
J.Hoernschemeyer,
D.Hoffmann,
T.Kolter,
G.Schwarzmann,
and
K.Sandhoff
(2004).
Photoaffinity labelling of the human GM2-activator protein. Mechanistic insight into ganglioside GM2 degradation.
|
| |
Eur J Biochem, 271,
614-627.
|
 |
|
|
|
|
 |
M.Zarghooni,
S.Bukovac,
M.Tropak,
J.Callahan,
and
D.Mahuran
(2004).
An alpha-subunit loop structure is required for GM2 activator protein binding by beta-hexosaminidase A.
|
| |
Biochem Biophys Res Commun, 324,
1048-1052.
|
 |
|
 |
 |
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
code is
shown on the right.
|
|